Ask AI
ProCE Banner Activity

What’s Next in MS Care: Guidelines & Pipeline

Podcast Episodes

Patricia K. Coyle, MD, FAAN, FANA, turns multiple sclerosis guidance into real-world decisions, from setting expectations and monitoring to knowing exactly when it’s time to switch. Dive inside the pipeline, including CNS-penetrant BTK inhibitors and other emerging therapies that could reshape progressive MS care.

Released: March 13, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for healthcare professionals in neurology who provide care for patients with MS, including physicians, nurse practitioners, physician associates, and pharmacists. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the immunopathogenic mechanisms and biologic basis of MS in the context of available treatment options

  • Evaluate clinical trial data on approved and emerging DMTs for relapsing MS

  • Apply efficacy, safety, and disease activity metrics to tailor treatment selection and monitoring plans for relapsing MS

  • Incorporate evidence-based communication techniques and multidisciplinary care approaches to support shared decision-making, improve adherence, and optimize long-term outcomes in MS management

Disclosure

Primary Author

Patricia K. Coyle, MD, FAAN, FANA: consultant/advisor/speaker: Accordant, Amgen, GSK, Horizon Therapeutics, Novartis, Sanofi Genzyme; researcher: CorEvitas, Genentech/Roche, Sanofi Genzyme.